コンテンツへスキップ
Merck

Long-term results of cornea collagen cross-linking with riboflavin for keratoconus.

Indian journal of ophthalmology (2013-08-09)
Vinay Agrawal
要旨

Corneal collagen cross-linking with riboflavin and UVA light (CXL) is the only method designed to arrest the progression of keratoconus. Visual improvement generally starts 3 months after treatment. Reduction is coma seen on aberrometry in early postoperative phase is also responsible for the improvement in visual acuity. In the light of currently available data we can thus say that CXL is a safe procedure that is successful in arresting keratoconus.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
(−)-リボフラビン, from Eremothecium ashbyii, ≥98%
Supelco
リボフラビン (B2), analytical standard
Sigma-Aldrich
(−)-リボフラビン, BioReagent, suitable for cell culture, suitable for insect cell culture, ≥98%
Supelco
リボフラビン, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Riboflavin, meets USP testing specifications
USP
(−)-リボフラビン, United States Pharmacopeia (USP) Reference Standard
(−)-リボフラビン, European Pharmacopoeia (EP) Reference Standard
(−)-リボフラビン, European Pharmacopoeia (EP) Reference Standard